Johnson & Johnson acquires Firefly Bio for $1 billion to boost oncology pipeline
Johnson & Johnson announced on June 8, 2026, its $1 billion cash acquisition of biotech startup Firefly Bio. The deal leverages Firefly’s Firelink platform, a novel degrader antibody conjugate (DAC) technology targeting hard-to-treat cancers driven by KRAS mutations. The acquisition aims to expand J&J’s oncology pipeline and is expected to close by end of 2026, pending regulatory approvals.
Cross-source coverage
Wire timeline
Johnson & Johnson Acquires Firefly Bio for $1 Billion to Target 'Undruggable' KRAS Cancers
Johnson & Johnson (JNJ) has acquired Firefly Bio for $1 billion in cash, gaining its proprietary Firelink degrader antibody conjugate (DAC) platform. This technology targets KRAS-driven tumors, long considered 'undruggable' in cancers such as colorectal, non-small cell lung, and pancreatic cancer. The acquisition is part of J&J's broader strategy to reach $50 billion in annual oncology revenue by 2030, following earlier purchases of Halda Therapeutics and Ambrx Biopharma. The Firelink platform enhances antibody drug conjugates (ADCs) by destroying gatekeeping proteins on diseased cells, improving drug penetration. The global oncology market, currently worth $280 billion, is projected to grow to $700 billion by 2035, positioning J&J favorably for future growth.
Yahoo FinanceJohnson & Johnson Acquires Firefly Bio for $1 Billion to Target Hard-to-Treat Cancers
Johnson & Johnson (JNJ) announced on June 8, 2026, that it will acquire privately held biotech startup Firefly Bio for $1 billion in cash. The deal centers on Firefly's Firelink platform, a novel degrader antibody conjugate (DAC) technology designed to attack tumors driven by the KRAS protein, which is notoriously difficult to treat and linked to lung, colon, and pancreatic cancers. Unlike traditional antibody-drug conjugates that deliver toxic payloads, Firefly's DACs deliver a 'degrader' molecule that marks harmful proteins for destruction within cancer cells, aiming to hit tumors harder while sparing healthy tissue. This marks Johnson & Johnson's second major acquisition in this space since early 2024, following its $2 billion purchase of Ambrx Biopharma. The acquisition is expected to close later in 2026 pending regulatory approval. The company's stock has been performing strongly, with Morgan Stanley recently raising its price target to $283.
Yahoo FinanceJohnson & Johnson acquires Firefly Bio for $1 billion to expand oncology pipeline
Johnson & Johnson announced on June 8, 2026, that it has agreed to acquire Firefly Bio, Inc. for $1 billion in cash, aiming to bolster its cancer drug pipeline. The deal centers on Firefly's proprietary Firelink platform, which delivers protein-degrading drugs into cancer cells via antibodies, targeting tumors driven by KRAS gene mutations—a historically 'undruggable' target. J&J's executive vice president John Reed highlighted the platform's potential to overcome current treatment limitations for solid tumors. The acquisition is expected to close by the end of 2026, pending regulatory approvals. This move comes amid strong momentum for J&J's Innovative Medicine segment, which reported first-quarter revenue of $24.1 billion, up 10% year-over-year, partly driven by oncology drug Darzalex. J&J also recently committed over $1 billion to build a cell therapy manufacturing facility in Pennsylvania.
Yahoo FinanceJohnson & Johnson acquires Firefly Bio for $1 billion
Johnson & Johnson has agreed to acquire Firefly Bio, Inc. for $1 billion in cash, expanding its oncology pipeline with Firefly's Firelink platform. The platform is designed to deliver protein-degrading drugs into cancer cells via antibodies, targeting tumors driven by KRAS gene mutations, which have been considered difficult to treat. J&J's executive vice president John Reed highlighted the potential to overcome limitations of current treatments. The deal is expected to close by the end of 2026, pending regulatory approvals. The acquisition comes amid strong momentum for J&J's Innovative Medicine segment, which reported Q1 2026 revenue of $24.1 billion, up 10% year-over-year, and raised its full-year sales outlook to $100.3-$101.3 billion.
Yahoo FinanceJ&J to buy cancer drug technology developer Firefly Bio for US$1 billion
Johnson & Johnson announced on Monday, June 8, 2026, that it will acquire biotech company Firefly Bio for US$1 billion in cash. The acquisition aims to expand J&J's cancer drug pipeline. Firefly Bio is known for its Firelink platform, a technology for developing cancer drug conjugates. The transaction is expected to close later in 2026. The news was reported by The Business Times in Singapore.
The Business TimesJ&J to buy cancer drug technology developer Firefly Bio for US$1 billion
Johnson & Johnson announced on Monday, June 8, 2026, that it will acquire biotech company Firefly Bio for US$1 billion in cash. The acquisition is aimed at expanding J&J's cancer drug pipeline, specifically leveraging Firefly's Firelink platform technology. The transaction is expected to close later in 2026. The news was reported by The Business Times in Singapore.
The Business Times